What is Imdevimab?
Due to the prevalence in this Omicron BA.2 sub-variant, this drug is currently not approved in any US region. Therefore it cannot be administered to treat COVID-19 in the EUA until further notice from FDA. US FDA. Imdevimab is an experimental drug that is being researched for its treatment of diseases that are caused by coronavirus. It isn't yet clear whether imdevimab is a secure and efficient treatment for any disease.
Imdevimab and casirivimab are both suitable for people with COVID-19 exposure. They include:
- Aren't fully protected against COVID-19 or
- Are vaccinated, however they might not have developed adequate immunity (because they suffer from certain diseases or are taking certain medications) and are or might have been exposed to individuals who have COVID-19.
Imdevimab and casirivimab are intended for use by adults and children aged 12 or older that weigh not less than 88 lbs (40 kgs).).
The likelihood of COVID-19 symptoms becoming more severe is higher in those who:
- Are overweight;
- Suffer from chronic kidney disease that is chronic;
- Are suffering from an autoimmune disease;
- Are immune systems that are weak (caused through illness or taking certain medications);
- Suffer from sickle cell disease.;
- Are suffering from a heart condition and/or have high blood pressure;
- Suffer from a neurodevelopmental disorder, like the cerebral ailment;
- Are suffering from an asthma or another breathing disorder, or
- Include a tracheostomy or gastrostomy or positive pressure vent (not associated with COVID-19).
There is also an increased risk of having severe COVID-19 symptoms among pregnant women and adults who are aged 65 or older. Imdevimab as well as casirivimab are combined to create a unique solution known as Regen-Cov. Imdevimab and casirivimab aren't approved for the treatment of coronavirus and COVID-19. However, these medications could assist in avoiding the requirement for medical emergency treatment or admission to a hospital due to COVID-19. Regen-Cov is not approved to be used by patients who are currently in a hospital or receiving oxygen supplemental for COVID-19.
Imdevimab can also be employed for other purposes that are not covered in this medication guide.
Side effects of Imdevimab
Contact a medical professional immediately. Get medical attention immediately if you notice symptoms warning signs of an allergic reaction, such as an allergic reaction that causes hives, itching or breathing problems or swelling of your lips, face and tongue.
Certain side effects can occur after the injection. Inform your doctor immediately If you experience:
- Inflammation of the throat, swelling of your throat or face;
- Lightheadedness, dizziness (like it's possible to faint);
- Chest pains, wheezing, shortness of breath;
- Fever the chills sweating, nausea flushing (sudden redness, warmth or tingly sensation);
- Rapid or slow heartbeats, headache, the pounding of your neck or ear;
- Weakness, tiredness;
- Itching, rash itching,
- Muscle pain.
Contact your physician If you experience symptoms that are getting worse or new following the infusion for example, fatigue, confusion, fever and fatigue, breathing problems or having fast or slow heartbeats. A few less serious side effects can be experienced as well, or you may experience none whatsoever. The possible effects of negative effects are a known fact. This is not a comprehensive list of all side effects. others could happen. Contact your physician for advice regarding medical effects. You may report any adverse reactions to the FDA at 1-800-FDA-1088.
Due to the prevalence in this Omicron BA.2 sub-variant, this drug is currently not approved in any US area; consequently it cannot be used for the treatment of COVID-19 as per the EUA until further notice from FDA. US FDA.
Before you take this drug
Speak to your doctor if were ever diagnosed with:
- A COVID-19 vaccine;
- An extreme allergic reaction to the COVID-19 vaccine
- Any chronic or severe disease;
- Any allergies or
- If you are pregnant or lactating.
COVID-19 is more likely to cause severe illness or even death in pregnant women. There aren't any known risks yet, however being treated by imdevimab and casirivimab are more likely to not be dangerous than being infected by COVID-19 in pregnancy.
What is the procedure for granting imdevimab?
Imdevimab as well as casirivimab (Regen-Cov) are to be used in combination. Imdevimab is not recommended to be taken on its own.
Regen-Cov is injected beneath either the skin, or in an existing vein by a healthcare professional. In the event of injection into a vein or vein, Regen-Cov is given slowly, over between 20 and 50 mins, or even longer. When it is injected through the skin, Regen Cov is administered as two to four injections to different areas of the body.
You will be monitored for a brief period after injection to ensure there isn't the reaction of an allergy. The Regen-Cov medication is typically administered in a single dose the earliest possible following exposure to or tested positive for COVID-19. This is usually within 10 days of the first signs of symptoms. It is possible that you will require additional monthly doses should you continue to be exposed to COVID-19.
The treatment by Regen-Cov won't cause you to be less prone to infect others. Keep using the appropriate infection techniques to control it, such as isolation, social distancing, hand washing, wearing a protective face cover, disinfecting surfaces that you frequently touch and avoiding sharing personal items with other people. Regen-Cov may not prevent you from getting infected with coronavirus in the future. The treatment combination may also impact the immune system of your body to a coronavirus vaccination. Imdevimab as well as casirivimab remain being researched and the risks associated with them aren't yet identified.
What happens if I miss the dose?
Consult your doctor for the proper dosage If you're on a dose schedule for a monthly period and miss an appointment for the injection.
How do I react if I consume too much?
In a medical environment, an overdose could be immediately treated.
What should be avoided?
Follow the instructions of your physician regarding any restrictions regarding drinks, food or activities.
Interaction with other drugs
Other drugs can interact with imdevimab. These include prescription and non-prescription medications, vitamins, and herbal products. Inform your physician about any other medications you take.
Keep this medication and other medications out of reach of children. Never let your medications be shared with anyone else. Use this medication only for the purpose prescribed. Always consult your physician to make sure the information presented on this page is applicable to your specific situation.